$GENFLEET-B (02595.HK)$ was listed on the Hong Kong Stock Exchange on September 19, with CITIC Securities acting as the sponsor. The public offering was oversubscribed by 2,662 times, making it one of the most popular biopharmaceutical IPOs recently. After surging 110% in the gray market yesterday, the stock soared over 140% on its debut today, reaching HK$50.2 at its peak. The company focuses on the R&D of innovative drugs for oncology and immune diseases, with its core product GFH925 being the first approved KRAS G12C inhibitor in China for the treatment of non-small cell lung cancer, demonstrating significant market potential. What is your view on GenFleet Therapeutics' first-day performance? Would you consider buying at the high or adopt a wait-and-see approach?